Abstract | Brain endocannabinoid (eCB) signalling influences the motivation for natural rewards (such as palatable food, sexual activity and social interaction) and modulates the rewarding effects of addictive drugs. Pathological forms of natural and drug-induced reward are associated with dysregulated eCB signalling that may derive from pre-existing genetic factors or from prolonged drug exposure. Impaired eCB signalling contributes to dysregulated synaptic plasticity, increased stress responsivity, negative emotional states and cravings that propel addiction. Understanding the contributions of eCB disruptions to behavioural and physiological traits provides insight into the eCB influence on addiction vulnerability.
The brain reward system is critical for survival. The hedonic effects produced by eating, exercise and sexual activity provide important motivational effects that increase the likelihood of future engagement in these criti cal activities (that is, positive reinforcement). The reward system is also essential for important negative hedonic responses, in which aversive or unpleasant events (for example, sickness or bodily harm) increase the likeli hood of behaviours that will avoid or relieve these negative states (that is, negative reinforcement).
Seminal discoveries demonstrating that the effects of marijuana (cannabis sativa) are mediated by canna binoid receptors in the brain propelled significant research initiatives that expanded our knowledge about the body's endogenous cannabinoid system (termed the endocannabinoid (eCB) system (ECS)), which is now acknowledged to have a prominent role in modulat ing brain reward function and maintaining emotional homeostasis. This Review examines the evidence for an eCB influence in the positivereinforcing effects of natural rewards and drugs of abuse. In contrast to the initial pleasurable experience of rewarding stimuli, pro longed drug exposure contributes to aberrant synaptic plasticity, negative emotional states and impaired learn ing and memory processes that sustain compulsive drug consumption, which is characteristic of the addicted state. We explore the ECS signalling underlying these maladaptive processes and provide an overview of the existing literature regarding the genetic factors that are associated with the ECS to gain insight about the potential contribution of ECS signalling dysregulation to addiction disorders.
The ECS and reward circuits
The ECS comprises G proteincoupled receptors and small neuromodulatory lipid ligands, as well as bio synthetic and metabolic enzymes for the synthesis and degradation of the ligands, respectively. Two major types of cannabinoid receptor have been characterized and cloned: cannabinoid 1 receptors (CB1Rs; encoded by CNR1) and CB2Rs (encoded by CNR2). CB1Rs are the mostabundant G proteincoupled receptors that are expressed in the adult brain, and they show particularly dense expression in regions that have a known involve ment in reward, addiction and cognitive function, including the amygdala, cingulate cortex, pre frontal cor tex (PFC), ventral pallidum, caudate putamen, nucleus accumbens (NAc), ventral tegmental area (VTA) and lateral hypothalamus 1, 2 . CB2Rs are expressed mainly by immune cells, although recent evidence suggests that such receptors are also expressed in neurons, glia and endothelial cells in the brain 3 . CB1Rs and CB2Rs are coupled to similar transduction systems, primarily through G i or G o proteins. CB1Rs directly inhibit the release of GABA, glutamate and acetylcholine, which produce widespread effects on neural signalling across many neurotransmitter systems.
To date, the bestcharacterized eCB ligands are Narachidonylethanolamide (anandamide (AEA)) and 2arachidonoylglycerol (2AG). Owing to their lipid nature, AEA and 2AG are not stored in vesicles but are synthesized 'on demand' by cleavage of membrane pre cursors and immediate release through Ca 2+ dependent mechanisms. AEA is derived from the phospholipid precursor Narachidonoylphosphatidylethanolamine
Synaptic plasticity
The process by which synaptic communication strengthens or weakens as a result of changes in morphology, composition or signal-transduction efficiency in response to intrinsic or extrinsic signals.
(NAPE) and, although the precise mecha nisms for AEA formation are not known, Nacyl phosphatidylethanolaminespecific phospholipase D (NAPEPLD) is likely to have a role in this process. 2AG derives primarily from the hydrolytic metabolism of 1,2diacylglycerol (DAG) by the sn1selective DAG lipases (DAGLs) DAGLα and DAGLβ. AEA is primar ily catabolized by fatty acid amide hydrolase 1 (FAAH1), and 2AG is catabolized by monoacylglycerol lipase (MAGL) and, to a lesser extent, by α,βhydrolase 6 (ABHD6), cyclooxygenase 2 (COX2) and FAAH1. The eCB catabolic enzymes have distinct cellular anatomical locations, with MAGL being localized predominantly in presynaptic terminals and FAAH1 being localized to the postsynaptic domain of neurons (FIG. 1) . AEA and 2AG both exert agonist activity at CB1R and CB2R. AEA binds with slightly higher affinity to CB1R than to CB2R and, like Δ 9 tetrahydrocannabinol (Δ 9 THC; the main psychoactive component of the cannabis plant), AEA exhibits low efficacy as an agonist at both recep tors, producing submaximal signalling on binding. 2AG binds with essentially equal affinity at CB1R and CB2R and exhibits greater agonist efficacy than AEA. AEA and 2AG also exhibit agonist properties at several secondary receptors, including peroxisome proliferator activated receptors (PPARs), G proteincoupled receptor 55 (GPR55) and GPR119, and AEA exerts potent agonist effects at transient receptor potential (TRP) ion channels, including TRPV1.
Neurobiology of reward
Mesocorticolimbic dopamine (DA) pathways, which arise from the midbrain VTA, have a critical role in the mediation of reward. In particular, the VTA DA projec tion to the NAc (part of the ventral striatum) has a prom inent role in positive reinforcement (FIG. 2) , that is, the recognition of rewards in the environment and promo tion of goaldirected behaviour (approach behaviour), resulting in reward acquisition. Natural rewards, such as food, sex and exercise, and drugs of abuse -including psychostimulants (such as cocaine and amphetamine), nicotine, alcohol, opiates and cannabinoids -increase NAc DA levels, and this neurochemical response con tributes to subjective reward and positive reinforcement 4 .
Components of the limbic system are also innervated by VTA DA neurons, including the amygdala, hippo campus, orbitofrontal cortex and parts of the PFC. These regions are interconnected in complex circuits that involve excitatory (primarily glutamatergic) and inhibitory (primarily GABAegic) projections 5 . In broad, simplistic terms, amygdala circuits contribute to the for mation of associative reward and fearrelated memories, hippocampal circuits are critical for declarative memory functions and frontal cortical circuits mediate control of executive functions. In turn, innervation of the NAc by each of these circuits allows sensory and emotional information to be converted into motivational actions through the output to extrapyramidal motor systems. DA signalling in the dorsal striatum does not have a major influence in processing acute reward but has a key role in the development of compulsive forms of reward seeking and consumption 6 . These same circuits participate in negativereinforce ment mechanisms that promote behaviours for avoiding or relieving aversive states. In general, NAc DA levels are decreased by aversive conditions, such as unavoid able shock, chronic pain, certain patterns of over or undereating and withdrawal from addictive drugs, and the resultant increased activity of medium spiny out put neurons contributes to aversive states 5, 7 . Negative reinforcement mechanisms associated with abstinence from longterm access to palatable food or abused drugs are mediated in part by excessive influence of prostress signalling systems (such as corticotropinreleasing fac tor and dynorphin) and impaired function of antistress signalling systems (such as neuropeptide Y and nocicep tin) in stress circuits that involve the central nucleus of the amygdala (CeA), bed nucleus of the stria terminalis (BNST), frontal cortex and medial shell of the NAc 5, 8 . Thus, reward processing is mediated in large part through an interconnected network of structures, including the VTA, NAc, ventral pallidum, CeA, BNST and PFC. In addition to the wellknown involvement of DA described above, reward processing is heavily influ enced by many other systems, including the cholinergic, opioid peptide, glutamatergic and GABAergic systems. CB1Rs are present in each of the interconnected struc tures involved in reward 1, 2, 9 , where they exert widespread modulatory influences on excitatory and inhibitory signalling in a manner that influences reward process ing 10, 11 . In particular, eCBs have a prominent role in DAGLα is found on the plasma membranes of both dopaminergic and non-dopaminergic neurons in the ventral tegmental area (VTA), opposite cannabinoid 1 receptor (CB1R)-expressing glutamate and GABA axon terminals 200 . Termination of endocannabinoid (eCB) signalling is initiated by cellular reuptake followed by enzyme-mediated hydrolytic cleavage. 2-AG hydrolysis is primarily mediated by presynaptic monoacylglycerol lipase (MAGL), although postsynaptic enzymes, including α,β-hydrolase 6 (ABHD6), also contribute to 2-AG clearance. AEA hydrolysis occurs in postsynaptic cells through fatty acid amide hydrolase (FAAH). Although these mechanisms are depicted here in the VTA, the pre-and postsynaptic organization of eCB biosynthetic and hydrolytic enzymes is generally conserved throughout the brain. AA, arachidonic acid. 
Intracranial self-stimulation
An operant behavioural paradigm in which subjects produce a behavioural response (such as a lever press or wheel turn) to receive brief electrical pulses into specific regions in the brain reward pathways.
Conditioned place preference
(CPP). A behavioural paradigm used to study the rewarding and aversive effects of drugs through Pavlovian conditioning.
Self-administered
In a medical sense, when a pharmacological substance is purposefully delivered by test subjects to themselves. Operant self-administration is a behavioural procedure in which experimental subjects learn to produce an operant response (for example, a lever press or nose poke) to receive a drug reward (such as an intravenous infusion, a small bolus for oral consumption or delivery of a discrete bolus of vapour that is inhaled).
Discriminative stimulus
A stimulus in a drug-discrimination paradigm that the animal has learned to associate with a predictable consequence (whether rewarding or unrewarding) and that increases the elicitation of a specific behaviour by the animal.
finetuning the activity of the VTA-NAc DA projection and its influence on approach and avoidance behaviours that govern reward acquisition (FIG. 3) .
eCB signalling and reward Exogenous AEA and 2AG both increase extracellular DA levels in the NAc in a CB1Rdependent manner 12 , and the ECS exerts a strong influence on the finetuning of midbrain DAcell activity 13 . Through these and other interactions, the ECS has a prominent influence on the hedonic effects of natural rewards, such as food 14 , sexual activity 15 and social interaction 16 . This is mediated in part through a direct CB1R modulation of the mesolim bic DA response to natural reward 16 and through the interactions between the ECS and other signalling sys tems (such as those involving endogenous opioids and hypothalamic signalling molecules, among others) 17, 18 . The rewarding effects of cannabinoid receptor activation are underscored by the fact that cannabis is one of the mostwidely used illicit substances world wide. Δ 9 THC is the primary psychoactive constituent in cannabis and exhibits low efficacy as an agonist at CB1R and CB2R 19 . In animal models, both Δ 9 THC and synthetic CB1R agonists enhance brain reward func tion (as indexed by intracranial self-stimulation), produce rewarding effects in the paradigm of conditioned place preference (CPP) and are voluntarily self-administered (intravenously and also directly into the NAc shell and posterior VTA) 20 . These effects are critically reli ant on CB1R signalling and are highly dosesensitive, with a rapid shift to negativereinforcing effects with increasing dose.
In contrast to exogenous cannabinoid receptor ago nists, pharmacological enhancement of eCB levels gen erally does not produce rewarding effects per se. For example, in most animal studies, selective eCBclearance inhibitors do not support operant selfadministration, do not produce CPP and do not alter brain stimula tion reward thresholds in rats and mice 21 . Similarly, exogenously administered AEA or 2AG, or selective FAAH or MAGL inhibitors, do not produce Δ 9 THC like discriminative stimulus effects. However, exogenous AEA and 2AG both support operant selfadministra tion in squirrel monkeys 21 and produce rewarding and Δ 9 THClike effects in rats when they are administered after eCBclearance inhibition 9, 22 . Concurrent FAAH and MAGL inhibition in mice produces Δ 9 THClike dis criminative stimulus and behavioural effects 22, 23 . These findings suggest that robust engagement of eCB signal ling is needed to evoke rewarding effects. However, recent evidence indicates that squirrel monkeys with a history of AEA, nicotine or cocaine selfadministration will self administer the FAAH inhibitor URB694, although this compound does not produce Δ 9 THC or nicotinelike discriminative stimulus effects and does not increase mesolimbic DA release 24 . Although it remains to be determined whether URB694 will be selfadministered by drugnaive monkeys or other species, this observation indicates that FAAH inhibition is not aversive and may produce mildly rewarding effects.
Cannabinoid receptor involvement in non-cannabinoid drug reward. The presence of CB1Rs throughout brain reward circuits and the rewarding effects produced by CB1R activation allow for the possible influence of eCB signalling on the acute rewarding effects pro duced by noncannabinoid substances (the effects of CB1R and FAAH manipulations on noncannabinoid drug reward are summarized in TABLE 1) . In general, drugs that activate CB1Rs do indeed seem to facilitate the rewarding effects of noncannabinoid drugs. CB1R agonists increase the motivational and reinforcing effects of alcohol, nicotine and opiates, as indexed by animal models of drug reward (including the CPP and oper ant selfadministration assays), whereas diminished . In general, the expression patterns of endocannabinoid (eCB)-biosynthetic enzymes (for example, N-acyl-phosphatidylethanolamine phospholipase D (NAPE-PLD) and 1,2-diacylglycerol lipase-α (DAGLα)) and hydrolytic eCB-clearance enzymes (for example, fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL)) are similar to those for CB1Rs across the regions depicted here 201, 202 . Within the amygdala, CB1R, DAGLα, MAGL and FAAH expression is highest in the lateral and basolateral nuclei, with substantially lesser expression in the CeA 56, 201 . In the dorsal striatum, there is a comparable medial-lateral gradient of CB1R and DAGLα expression, with greater levels of expression evident in lateral aspects 201, 203 . Comparatively weaker CB1R, DAGLα and FAAH expression is observed in the NAc 201 . Although little to no CB1R expression is found in dopamine cells in the NAc, DAGLα has been found in both dopaminergic and non-dopaminergic cells in this region 204 . CRF, corticotropin-releasing factor. CB1R signalling (through either genetic deletion or pharmacological antagonism) attenuates the motiva tional and rewarding effects of these drugs 11, 25, 26 . The effects of CB1R antagonism on alcohol and nicotine reward result in part from a diminished ability of these drugs to increase NAc DA release 27 . Blockade of CB1Rs specifically in the VTA decreases alcohol and nicotine selfadministration 28, 29 , and blockade of CB1Rs spe cifically in the NAc reduces alcohol consumption 28, 30 . However, whereas nicotine reward is critically depend ent on the mesolimbic DA system 31 , the motivational and rewarding effects of alcohol and opiates are less 2-Arachidonoylglycerol (2-AG) produced by dopaminergic VTA neurons acts on cannabinoid 1 receptors (CB1Rs) on nearby glutamatergic and GABAergic terminals before being degraded by α,β-hydrolase 6 (ABHD6) or monoacylglycerol lipase (MAGL). CB1Rs mediate robust inhibition of GABA inputs arising from the pallidus, rostromedial tegmental (RMTg) nucleus and local interneurons onto VTA dopamine (DA) cells 205 , and most evidence points to a role for 2-AG but not N-arachidonylethanolamide (anandamide (AEA)) in these processes 109, 206 . CB1Rs are also localized on glutamatergic terminals synapsing on VTA DA neurons, with relatively greater expression on vesicular glutamate transporter 1 (VGLUT1)-positive terminals of cortical origin compared with VGLUT2-expressing terminals of subcortical origin 207 . Extensive evidence demonstrates eCB-mediated suppression of glutamate signalling in the VTA 208 . Thus, eCBs have a prominent role in fine-tuning the activity of the mesolimbic DA projection through modulation of both excitatory and inhibitory signalling in the VTA. b | The eCBs also influence nucleus accumbens (NAc) synaptic signalling. The majority of NAc neurons (>90%) are GABAergic medium spiny neurons (MSNs) that comprise the directand indirect-projection pathways. Direct-pathway MSNs (dMSNs) project to midbrain regions, including the VTA, and activation of this pathway increases behaviour towards a stimulus (approach or appetitive behaviour). Indirect-pathway MSNs (iMSNs) project to the ventral pallidum (VP), and activation of this pathway increases stimulus avoidance 209 . dMSNs express excitatory D1 DA receptors (D 1 Rs), whereas iMSNs express inhibitory D 2 Rs; thus, reward-related phasic DA release activates the direct pathway and inhibits the indirect pathway, thereby increasing approach behaviour and reducing avoidance behaviour 210 . NAc MSN activity is also heavily modulated by glutamatergic inputs from the prefrontal cortex (PFC), basolateral amygdala (BLA) and ventral hippocampus (vHIPP), which express CB1Rs
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. CB1R-mediated suppression of excitatory signalling (eCB-mediated long-term depression (eCB-LTD)) is preferentially active at iMSN synapses 212 , possibly resulting from D 2 R-mediated eCB production from iMSN cell bodies 213 . Thus, increased NAc eCB formation preferentially reduces excitatory input to iMSNs versus dMSNs, resulting in decreased avoidance behaviour. Through these mechanisms, increased eCB signalling in the NAc increases approach behaviour while reducing avoidance-related processing, thereby enhancing appetitive responses towards a stimulus. CB1Rs are also expressed on terminals of fast-spiking interneurons (FSIs) in the NAc, the majority of which are electrically and chemically coupled and provide direct innervation to adjacent MSNs 214 . FSIs exert important influence on the synchronization of neural ensemble activity and thus eCB signalling may also exert critical influence on NAc output through feedforward modulation of MSN network activity 214 .
Non-contingent
Drug delivery that is involuntary (experimenteradministered) or is not dependent on a behavioural response by an experimental subject; sometimes referred to as forced administration.
DAdependent
32,33 , and the CB1R modulation of the rewarding effects of these drugs probably involves non dopaminergic mechanisms. Indeed, CB1R antagonism does not alter opiateinduced increases in NAc DA levels but reduces opiate reward through the preven tion of opiateinduced reductions in ventral pallidal GABA release 34 . In comparison to these drugs, CB1R manipulations on psychostimulant reward have mod est and lessconsistent effects. CB1R agonists reduce the facilitation of brain stimulation reward produced by cocaine and reduce cocaine selfadministration 35, 36 . Most reports indicate that CB1R antagonism does not affect psychostimulant reward (as assessed by cocaine induced enhancement of brain stimulation reward, CPP and selfadministration) or cocaineinduced increases in NAc DA levels 37 (but see REFS 27,37). Recent evidence in mice also implicates CB2Rs in the modulation of drug reward, including an inhibi tory influence on cocaine and alcohol reward 38, 39 but a facilitatory influence on nicotine reward 40, 41 . However, disparate observations have been made in rats 39, 42, 43 , and it is possible that these findings are influenced by species differences in CNR2 splicing that confer distinct CB2R structure, function or pharmacology 39 .
Alterations in brain eCB levels elicited by drugs of abuse.
Given the ondemand nature of eCB production and the associated modest eCB signalling tone under baseline conditions, the robust influence of cannabinoid receptor signalling on noncannabinoid drug reward has led to the hypothesis that drug exposure increases brain eCB formation. Substantial evidence demonstrates that there are alcoholinduced alterations in postmortem eCB con tent in the rodent brain, although inconsistencies among studies cloud definitive conclusions regarding the direc tion of change and the regional nature of the effects 44 . For example, alcohol exposure increases extracellular 2AG levels in rat NAc (measured by in vivo microdi alysis), and this is more pronounced following voluntary selfadministration than after non-contingent alcohol exposure 28, 30 . By contrast, extracellular AEA levels in the NAc are unaltered by alcohol selfadministration and are decreased by noncontingent alcohol administration. Alcohol also seems to induce regionspecific changes in braintissue eCB levels, with alcoholinduced disruptions being consistently observed in striatal regions 30, 45, 46 but not in frontal cortical areas 28 . This is consistent with evidence that alcohol consumption is reduced by CB1R antagonism in the VTA and NAc but not in the PFC 28, 30, 47 . Similarly to alcohol, nicotine alters eCB levels in the rodent brain, with factors such as the brain region evalu ated and the voluntary nature of drug exposure having important relevance to the effects observed. Repeated noncontingent nicotine injections increase AEA lev els in rat limbic forebrain and dorsal striatal tissue but decrease both AEA and 2AG levels in cortical tissue 48 . Intravenous nicotine selfadministration increases extra cellular levels of both AEA and 2AG in the rat VTA, and the effect on 2AG is sensitized by chronic nicotine exposure 49 . Interestingly, although VTA 2AG levels are elevated by both voluntary and noncontingent nicotine exposure, VTA AEA levels are increased only by vol untary nicotine selfadministration 49 . Together with the evidence of distinct patterns of brain eCB levels induced by volitional versus noncontingent alcohol exposure 28, 30 , these data suggest that brain eCB production is influ enced not only by drugrelated pharmacological effects but also by neural activity engaged by active drug self administration (possibly related to the motivation for drug consumption).
Relatively less is known regarding the effects of other rewarding drugs on brain eCB levels. Available evi dence consistently indicates that opiates increase AEA but decrease 2AG tissue concentrations in the striatum, limbic forebrain and hippocampus 50, 51 . Similarly, heroin selfadministration increases extracellular AEA with a concomitant decrease of extracellular 2AG levels in the . Psychostimulants generally produce modest disruptions in brain eCB content, with subtle increases and decreases in 2AG concentration in forebrain fol lowing noncontingent acute and chronic cocaine exposure, respectively (no other alterations are evident regardless of region analysed) 48, 52 . Moreover, voluntary cocaine selfadministration does not alter rat extracel lular NAc eCB levels 30 but decreases 2AG content in frontal cortex and hippocampal tissue [53] [54] [55] . Collectively, these findings indicate that alcohol, nicotine and opiates alter brain eCB content, consonant with the CB1R influence on the behavioural effects pro duced by these drugs. The generally modest effects of psychostimulants on brain eCB levels are inline with the subtle CB1R influence on psychostimulantinduced behaviours. Similarly to that seen with multiple biologi cal conditions, drug exposure often produces distinct and sometimes opposite effects on brain AEA and 2AG levels. This suggests differential regulation of the synthe sis and/or degradation of these eCB moieties at specific synapses that may arise from the segregation of MAGL and FAAH in the pre and postsynaptic compartments 56 , or the hypothesized role of AEA and 2AG in regulating 'tonic' and 'phasic' signalling in the ECS, respectively 57 . Although a general picture of druginduced alterations in brain eCB levels is emerging, experimental differ ences between studies -including the drug dose used, the method of drug exposure and the duration of treat ment -make it difficult to draw strong conclusions, and additional studies are warranted.
Influence of eCB tone on drug reward. eCBs are rap idly degraded, so strategies that reduce eCB clear ance have been used as a means to further investigate the eCB influence on drug reward. Most investiga tions have focused on the effects of FAAH inhibition, because selective tools for inhibiting MAGL and other eCBclearance enzymes were not available until recently. Such studies have shed light on important spe cies differences that confound the overall conclusions that can be made from existing data. For example, FAAH inhibition in mice increases nicotine reward in the CPP paradigm 58, 59 , but FAAH inhibition in rats pre vents nicotineinduced CPP, diminishes nicotine self administration and blunts nicotineinduced increases in NAc DA release 60 . The potentiation of nicotine reward in mice by FAAH inhibition is CB1Rmediated, whereas the reduction in nicotine reward in rats results from activation of PPARα by noncannabinoid lipids, such as oleoylethanolamide and palmitoylethanolamide, that are hydrolytically cleared by FAAH 61 . FAAH inhibition also produces distinct speciesrelated alterations in alco hol consumption, with increased intake being observed in mice but not in rats [62] [63] [64] [65] . The mechanisms underlying these differences are not understood. Brain regionspe cific disruptions in FAAH activity may be an important factor. In regard to alcohol reward, inhibition of FAAH activity specifically in the PFC results in increased alco hol consumption, and rats selectively bred for high alco hol intake and preference are characterized by reduced FAAH activity specifically in the PFC 64, 65 . The effects of FAAH inhibition on opiate and psychostimulant reward have primarily been studied in rats. FAAH inhibition does not alter morphine or cocaineinduced disrup tions in VTA DAcell firing or the selfadministration of either drug 66, 67 . However, FAAH inhibition diminishes cocaineinduced alterations in NAc mediumspiny neu ron activity 68 , and this may contribute to enhanced sen sitization of both cocaineinduced motor activity and mesolimbic DA responses following repeated cocaine exposure 69 . Other studies have investigated the effects of putative eCB transport inhibitors, such as AM404 and VDM11, and the findings thus far suggest that these compounds produce subtle and inconsistent effects on nicotine and cocaine reward [70] [71] [72] [73] . Although growing evidence implicates ECS influences in the modulation of acute drug reward, additional efforts are needed to further clarify the nature of eCB disrup tions caused by different classes of abused drug and the neural mechanisms through which these eCB influences are mediated. Selective inhibitors of 2AG clearance have recently been developed, but studies using them are still in their infancy and there are presently no published reports on the effects of enhanced 2AG tone on drug reward and related physiological events. As such, there remains a substantial gap of knowledge, given the prominent 2AG influence on neural signalling and plasticity related to both drug and natural rewards. Nevertheless, the role of the CB1R in drug reward is unequivocal and, although there is evident complexity related to the effects produced by eCBclearance inhibition (producing discrete modula tion of eCB tone in specific synapses and circuits when compared with broad CB1R activation by exogenous CB1R agonists), the extant evidence strongly supports an eCB influence on the sensitivity to, and motivation for, several drugs of abuse.
eCB signalling in addiction Numerous factors influence the transition from inter mittent, controlled drug use to the compulsive forms of drugseeking and drugtaking behaviour that charac terize addiction. Substantial evidence implicates genetic influences in the development of substanceuse disor ders (SUDs) and pathological forms of eating, sexual behaviour and gambling 74 , and it is increasingly recog nized that epigenetic mechanisms drive lasting changes in addictionrelated gene expression 75 . Longterm drug exposure induces lasting neuroadaptations in motiva tional mechanisms that propel drugseeking behaviour and drug use. Although initial drug use is motivated by hedonic processes, prolonged drug exposure progres sively blunts reward system function, thereby leading to escalated frequency and amount of drug consumption, resulting in a dependent state wherein negative affective symptoms (for example, dysphoria, anxiety and irritabil ity) emerge during abstinence. These negative emotional states arise from the recruitment of stress signalling sys tems (such as corticotropin releasing factor and dynor phin) and dysregulation of mechanisms that constrain these responses (such as neuropeptide Y and nociceptin) within the extended amygdala 5 . Renewed drug consump tion alleviates these negative affective states, and this is
Conditioned reinforcement
The process through which neutral stimuli acquire motivational properties through association with a primary reinforcer.
Stochastic optical reconstruction microscopy
conceptualized to motivate compulsive drug use through negative reinforcement 5 . Superimposed on these pro cesses is a dysregulation of corticostriatal mechanisms mediating stimulus-response learning, constraint of impulsivity, conditioned reinforcement and incentive moti vation, resulting in a narrowed focus on drugseeking at the expense of natural rewards 6 . eCBs exert prominent modulatory influence on the extended amygdala and corticostriatal circuits 5, 32 , and increasing evidence suggests that preexisting genetic influences on the ECS and/or druginduced dysregula tion of eCB function participate in the development and maintenance of addictions, including pathological forms of eating
Chronic drug exposure and eCB function. It is unsur prising that chronic cannabis use disrupts brain can nabinoid receptor availability and function. Using the in vivo technique of positron emission tomography (PET) imaging, one study 76 reported that there was downregu lation of brain CB1Rs in daily cannabis users, that the level of downregulation correlated with the number of years of cannabis use and that this downregulation was reversed after 1 month of monitored abstinence. Another PET study reported a global reduction in CB1R avail ability 77 driven by differences in the temporal lobe, ante rior and posterior cingulate cortex and NAc. Similarly, animals given noncontingent chronic cannabinoid exposure exhibit decreased CB1R function throughout the brain 78, 79 . Recent experiments using stochastic optical reconstruction microscopy demonstrate that chronic expo sure to clinically relevant doses of Δ 9 THC results in a startling loss of CB1Rs on terminals of perisomatically projecting GABAergic interneurons in the mouse hippo campus and internalization of the remaining CB1Rs 80 . The resulting deficits in inhibitory CB1R control over hippocampal GABA release persisted during several weeks of Δ 9 THC abstinence, and this may underlie the enduring loss of hippocampal longterm potentiation (LTP) in rodents and memory deficits in humans evident following chronic cannabinoid exposure 81 . Surprisingly little is known of the effect of chronic cannabinoid exposure on other facets of ECS function. Chronic cannabinoid exposure increases enzymatic clearance of AEA and reduces brain tissue AEA content in rodents 82, 83 , and frequent cannabis smokers present decreased AEA and increased 2AG levels in blood 84, 85 , although increased serum AEA levels are evident follow ing at least 6 months of cannabis abstinence 86 . The con tribution of these disruptions to cannabisuse disorder and related physiological and behavioural disruptions is presently unexplored. However, as discussed below, eCBs provide important homeostatic constraint over emotional state 87 and sleep function 88 , and it is conceiv able that Δ 9 THCinduced impairment of eCB signal ling contributes to the negative emotional states and sleep disturbances present during protracted cannabis abstinence 89, 90 . Several findings support the hypothesis that chronic exposure to noncannabinoid drugs disrupts eCB signal ling and processing. Chronic alcohol exposure in rodents alters eCBrelated gene expression in a manner sensitive to the intermittent nature of alcohol exposure and post alcohol abstinence period 91 and downregulates CB1R expression and function 45, 92 . Postmortem studies of alcoholdependent humans also demonstrate disrupted CB1R expression in the ventral striatum and corti cal regions 93 , and in vivo imaging studies demonstrate decreased CB1R availability in heavydrinking alco holics that persists for at least 1 month of abstinence 94, 95 (but see REF. 96 ). Although a potential contribution of variants of CNR1 (which encodes CB1R) to these obser vations cannot be excluded, a common interpretation based on animal studies is that these CB1R adaptations in humans with alcoholism are a consequence of pro longed alcoholinduced increases in brain eCB levels. This is supported by evidence of transient recovery (and perhaps eventual upregulation) of CB1R function in humans during protracted alcohol abstinence 92, 97 . In rodents, chronic nicotine exposure induces distinct agerelated disruptions in CB1R binding, with increased levels being evident in the PFC, VTA and hippocampus
Box 1 | Endocannabinoid signalling and eating disorders
Food and drug addiction derive in part from aberrant brain reward function and share overlapping neuroadaptations in the mesolimbic system 176 . Similarly to drug addiction, food addiction is defined by compulsive over-or under-eating, aberrant feeding despite negative consequences and unsuccessful attempts to 'normalize' dysfunctional eating.
The rewarding effects of self-starvation or binge eating may involve disrupted endocannabinoid (eCB) function 177 . Anorexia nervosa and binge-eating disorder are associated with increased blood N-arachidonylethanolamide (anandamide (AEA)) levels and diminished levels of leptin 178 (an anorectic hormone that inhibits AEA synthesis). Anorexia is associated with a CNR1 (the gene encoding cannabinoid 1 receptor (CB1R)) AAT-triplet repeat ((AAT) n ) polymorphism 179 (but see REF. 180 ) and a synergistic association between the C385A fatty acid amide hydrolase (FAAH) and CNR1 rs1049353 polymorphisms 181 . The C385A FAAH polymorphism is also associated with obesity 182 , although it is unknown whether this may influence hedonic mechanisms, metabolism or both. Anorexia and bulimia nervosa are also associated with elevated plasma CNR1 mRNA levels 183 , increased CB1R availability in frontal cortical areas 184 and a nonsynonymous CNR2 (the gene encoding CB2R) polymorphism 185 . Preclinical models of anorexia suggest therapeutic effects for Δ 9 -tetrahydrocannabinol (Δ 9 -THC) 186 (but see REF. 187 ). Although two small clinical trials did not show Δ 9 -THC efficacy 176 , a larger trial demonstrated small but significant weight gain in women with severe anorexia nervosa following 4 weeks of treatment with dronabinol 188 . Conversely, in binge-eating disorder, the CB1R antagonist rimonabant significantly reduces binge eating and promotes weight loss, with only modest presentation of psychiatric side effects 189, 190 . A withdrawal state similar to that associated with drugs of abuse is evident in rats during forced abstinence from highly palatable food 191, 192 , with symptoms including increased anxiety and excessive consumption on renewed access to palatable food. These symptoms result from increased corticotropin-releasing factor 1 (CRF1; also known as CRHR1) signalling in the central nucleus of the amygdala (CeA) 8 and are reversed by increased CeA 2-arachidonoylglycerol (2-AG)-CB1R signalling 193 . This suggests that dysregulated CeA function is a common factor contributing to pathological motivation for drugs and food, and that CeA eCB signalling may counter withdrawal-related stress signalling.
of adolescent, but not adult, rats 98 and increased hip pocampal and decreased striatal CB1R binding being seen in adult rats during protracted nicotine absti nence 99 . Few studies have investigated altered CB1R binding following chronic opiate or psychostimulant exposure, but findings in rodents implicate impaired CB1R function in the development and expression of opiate dependence 100, 101 and demonstrate that chronic cocaine use increases CB1R binding in the dorsal stria tum, NAc and cortical areas 102 . Interestingly, detoxified cocaine addicts present significant increases in plasma AEA and decreases in plasma 2AG content 103 , but the functional consequence of these disturbances is not known. Overall, accruing data suggest that longterm exposure to various drug classes compromises eCB processing and CB1R expression and function. As dis cussed below, these perturbations may contribute to aberrant neural signalling during acute and protracted drug abstinence.
Addiction-related synaptic plasticity. The development and persistence of addiction is attributed to maladaptive synaptic plasticity evident in the neuronal reorganization (molecular, cellular and functional activity) of meso corticolimbic and striatal pathways. eCB signalling at CB1Rs is implicated in several forms of synaptic plasticity, most commonly in depolarizationinduced suppression of excitatory transmission (DSE) or inhibitory transmis sion (DSI), shortterm depression (STD) and longterm depression (LTD; a prolonged form of weakened synaptic strength) 68, 104 . STD, DSE and DSI are mediated primarily by 2AG signalling, typically persist for a minute or less, and have been observed in brain areas relevant to reward and addiction, including the VTA, basolateral amyg dala, hippocampus, neocortex and substantia nigra 10 . By comparison, eCBmediated LTD can persist for hours or weeks, is particularly important in learning and memory, and has also been observed in addictionrelated regions, including the NAc, VTA, amygdala, PFC, hippocampus and dorsal striatum 10 . Acute and chronic alcohol exposure reduces CB1Rdependent plasticity, resulting in longlasting disinhibition of striatal output neurons and diminished eCBmediated LTD (eCBLTD) at inhibitory striatal synapses 105, 106 . Because the dorsal striatum mediates rewardguided learning and habitual behaviour, these eCB disruptions may contribute to maladaptive habitual behaviour that perpetuates addiction 107 . Cocaine dimin ishes eCBLTD of excitatory transmission in the NAc 108 and facilitates eCBLTD of inhibitory signalling at VTA DA synapses 109, 110 , resulting in diminished inhibi tory control over VTA DAcell activity and heightened excitatory signalling in the NAc (FIG. 4) . Cocaine also disrupts eCBLTD of excitatory transmission in the BNST 111 , a component of the extended amygdala, and this may contribute to aberrant stress-reward inter actions (via projections to the VTA) 112 and excessive anxietylike behaviour. Similarly, chronic Δ 9 THC or synthetic CB1R agonist exposure abolishes eCBLTD of excitatory and inhibitory signalling in the NAc and hippocampus 113, 114 , which may significantly affect reward processing mediated by these regions. Little is known regarding opiate or nicotineinduced disrup tions in eCBmediated synaptic plasticity, although cueinduced reinstatement of nicotineseeking behav iour (an animal model of relapse) relies in part on the induction of CB1Rmediated LTP of cortical synapses in the BNST 115 . Thus, chronic drug exposure disrupts eCB mediated forms of synaptic plasticity in several regions involved in reward processing. As discussed below, impaired eCBmediated plasticity may also contribute to dependencerelated affective disruptions that serve to sustain drug dependence.
Withdrawal-related affective disruption. Stress has a prominent role in the development of addiction 116 , and stress exposure disrupts eCBmediated plasticity in regions that participate in emotional control, includ ing the NAc, amygdala and BNST 117 . Withdrawal from most drugs of abuse is associated with increased stress responsivity and persistent negative affective symp toms, such as anxiety and depression, the severity of which are closely associated with relapse susceptibility. Comorbidity of affective disorders and SUDs is preva lent, and preexisting negative affective traits may be an antecedent to addiction. The ECS participates in a negativefeedback system that constrains emotional distress under stressful circumstances and contrib utes to the suppression of aversive memories 117, 118 . This function is reliant on eCBmediated forms of synaptic plasticity, and deficient eCB signalling is associated with increased anxiety and depression. As such, impaired eCB function may contribute to the negative affective states and increased stress responsivity that underlie negativereinforcement mechanisms driving drug use by dependent individuals and that contribute to drug relapse following periods of abstinence.
Mice lacking CB1Rs exhibit greater anxietylike behaviour than normal animals during nicotine with drawal 119 , although innate anxietylike behaviour in the knockout mice clouds interpretations. Studies evaluating eCBclearance inhibition provide moredirect insight into withdrawalrelated eCB disruption and negative affect. Acute FAAH inhibition reverses enhanced anx ietylike behaviour that is normally present during both nicotine and alcohol withdrawal 65, 120 , and the eCBtrans port inhibitor AM404 attenuates depressionlike behav iour during nicotine withdrawal 121 . Posttraumatic stress disorder is particularly prevalent among individuals with alcoholuse disorders, and this is often modelled in rodents using the fearpotentiated startle paradigm to study reflexive physiological reaction to a stimulus. Rodents selectively bred for high alcohol consumption exhibit greater fearpotentiated startle than corollary lines bred for low alcohol consumption 122, 123 . In addi tion, acute FAAH inhibition by LY2183240 reduces fearpotentiated startle in high alcoholpreferring, but not low alcoholpreferring, mice 124 , consistent with the efficacy of FAAH inhibition for accelerating the extinc tion of aversive memory 125 . LY2183240 also enhances the conditioned rewarding effects of alcohol without alter ing alcohol consumption itself, suggesting that FAAH Nature Reviews | Neuroscience Addiction-related learning and memory Both positive and negative memories and conditioned cues associated with drug use perpetuate drugseeking behaviour and the continued cycle of abuse. The ECS has a prominent role in learning and memory processes 126 , and CB1R signalling is strongly linked to the conditioned rewarding effects of alcohol, nicotine and opiates 11, 25 . Although druginduced conditioning effects are gener ally interpreted in the context of drug reward, a CB1R influence on the associative learning aspects of drug exposure is also possible, which as discussed below may have relevance to the persistent reactivity to drugrelated memories that characterizes addiction.
Drug-seeking (relapse).
Drug exposure produces pow erful interoceptive effects that become associated with environmental cues, such that these cues alone can induce craving and promote relapse following periods of abstinence 127 . In addition to conditioned drug memories, acute exposure to a preferred drug or pharmacologically related agent (that is, drug priming) and stressful events can precipitate relapse 116 .
Animal models of relapse demonstrate an impor tant cannabinoid influence on the reinstatement of extinguished drugseeking and drugtaking behav iours. Δ 9 THC and synthetic CB1R agonists reinstate drugseeking for cannabinoids, alcohol, nicotine, opi ates and cocaine, whereas CB1R antagonists attenuate drugseeking behaviour associated with each of these drugs 25, 128, 129 . CB1Rs in the PFC and NAc shell influence cueinduced reinstatement of both heroin and nicotine seeking behaviour, whereas CB1Rs in the basolateral amygdala contribute to cueinduced nicotine but not heroinseeking behaviour 130, 131 . Despite the subtle effects of CB1R inactivation on psychostimulant selfadminis tration, CB1R antagonism attenuates drugprimed, cue induced and some forms of stressinduced reinstatement of cocaine and methamphetamineseeking behaviour in Figure 4 | Drug-induced alterations in endocannabinoid-mediated synaptic plasticity. Simplified summary of the effects of cocaine, Δ 9 -tetrahydrocannabinol (Δ 9 -THC) and possibly other drugs of abuse on endocannabinoid-mediated long-term depression (eCB-LTD). a | Under normal circumstances, eCB-LTD is induced by afferent stimulation with or without postsynaptic depolarization, resulting in 2-arachidonoylglycerol (2-AG) formation from postsynaptic cells. 2-AG activates cannabinoid 1 receptors (CB1Rs) on stimulated or neighbouring, non-stimulated neurons, which together with other events (for example, increased [Ca +2 ], NMDA receptor (NMDAR) stimulation and dopamine (DA) D2 receptor stimulation) results in persistently decreased neurotransmitter release. The presynaptic signalling mechanisms contributing to eCB-LTD are not fully understood. Depending on brain region, eCB-LTD of both excitatory (glutamatergic; eCB-LTDe) and inhibitory (GABAergic; eCB-LTDi) afferents has been described. b | Repeated cocaine exposure facilitates eCB-LTDi in the ventral tegmental area (VTA) 109, 110 , resulting in diminished inhibitory constraint of VTA DA-cell activity and increased excitability. c | By contrast, eCB-LTDe is lost in the nucleus accumbens (NAc) medium spiny neurons (MSN) following exposure to either cocaine or Δ 9 -THC 108, 113, 114 , resulting in diminished constraint of glutamatergic release and increased excitation of NAc cells. Thus, drug exposure results in concurrent loss of eCB-mediated plasticity that normally provides inhibitory control over VTA DA-cell excitation and that normally constrains excitatory signalling in the NAc terminal region, conferring an overall enhancement of mesolimbic signalling. AEA, N-arachidonylethanolamide (anandamide); AMPAR, AMPA receptor; DAGL, 1,2-diacylglycerol lipase; FAAH, fatty acid amide hydrolase; GABA A R, GABA A receptor; mGluR, metabotropic glutamate receptor; NAPE, N-arachidonoyl-phosphatidylethanolamine; NAPE-PLD, N-acyl-phosphatidylethanolamine-specific phospholipase D. rats 25 . Thus, CB1R signalling modulates drugseeking for various pharmacologically distinct drugs. There is also evidence that CB1R antagonism blocks both cue and priminginduced reinstatement of seeking behaviour for nondrug rewards, such as sucrose and corn oil 132, 133 (but see REF. 134 ). Accordingly, CB1R signalling seems to participate in the modulation of conditioned reward in general.
Drugprimed and cueinduced nicotine and cocaine seeking behaviour are reduced following acute FAAH inhibition that leads to elevated AEA levels 25, 60 , which may be surprising considering that CB1R agonists enhance both nicotine and cocaineseeking behaviour 25 . However, inhibition of eCB clearance probably amplifies eCB sig nalling preferentially in circuits or synapses activated by a given stimulus (in this case, drugseeking behaviour), rather than inducing morewidespread indiscriminate CB1R activation, as produced by exogenous CB1R ago nists. Moreover, FAAH hydrolyses a large range of fatty acid moieties, and the effects of FAAH inhibition on drugseeking behaviour may involve noncannabinoid lipid signalling. In this regard, it is notable that the eCB transport inhibitor VDM11 attenuates both nicotine and cueinduced nicotineseeking behaviour 71 , and this compound may preferentially block AEA clearance with weaker effects on noncannabinoid lipids 135, 136 . Similarly, the eCB transport inhibitor AM404 dosedependently attenuates nicotine and cueinduced nicotineseeking behaviour without altering nicotine selfadministration 72 . In contrast to nicotine and cocaineseeking behav iours, neither FAAH inhibition nor eCB transport inhibition alter cue or stressinduced reinstatement of alcoholseeking behaviour 65, 137 . However, studies in humans with alcoholism suggest a relationship between eCB tone and craving that may relate to the degree of dependence and possibly inherent factors contributing to alcoholism vulnerability. In social drinkers, alcohol related cues increase both craving and plasma AEA levels, and the relative magnitude of cueinduced increases in AEA is significantly correlated with the degree of crav ing 138 . However, recently detoxified individuals with alco holism present significantly lower baseline plasma AEA levels than nondependent social drinkers and, although alcoholrelated cues elicit moreintense cravings in alco holics, these individuals do not present significant cue induced increases in plasma AEA. This blunted AEA response may reflect aberrant eCB processing in people with alcoholism, but further investigations are needed to confirm a direct link between this potential peripheral biomarker and brain eCB signalling, as well as possible causal relationships between dysregulated eCB processing and behaviour.
Extinction learning. The potent motivational effects of drugrelated cues create substantial difficulties during periods of attempted drug abstinence and are causal in the reinstatement of drug intake (for example, relapse) 127 . One approach for reducing the motivational impact of drug associated cues is through extinction training, in which a subject learns that these cues no longer have predictive value. However, extinction therapy is generally ineffective for reducing relapse in both humans 139 and rodents 140 , and it is conceivable this is a consequence of diminished learning mechanisms required to override the original cueassociation memory. The ECS has a prominent role in memory extinction, and deficient CB1R signalling results in impaired extinction of cued fear memory, contextual fear memory, fearpotentiated startle and spatial memory under mildly aversive conditions 141, 142 . Moreover, as previ ously noted, FAAH inhibition facilitates the extinction of fearful memory in mice selectively bred for high levels of alcohol preference and consumption 124 . Because aversive memory may be involved in relapse to drug taking 143 , deficient eCB signalling following longterm drug expo sure may contribute to the limited efficacy of extinction therapy for addiction.
eCB gene polymorphisms and addiction Approaches to explore the contribution of the ECS to addiction disorders in humans often involve heritability considerations, as it is now acknowledged that genet ics plays an important part in drug addiction vulner ability, accounting ~30-80% for risk depending on the drug class 144, 145 . Based on the growing evidence of a role for the ECS in regulating reward, mood and cognition and owing to its prominent expression within neuronal systems related to these functions, the ECS has been viewed as a central target for candidategene studies of addictive disorders. Similarly to the preclinical ani mal studies described above, most investigations have focused on CNR1 and FAAH 146, 147 . Consistent with most genetic investigations, important confounding factors include race, ethnicity, type of drug, polysubstance use and population sample size. Nevertheless, although they are not all equivocal, what can be garnered from existing genetic studies (although limited) suggests that genomic heterogeneity of the eCBrelated genes may influence in part substance abuse vulnerability and relate to behavioural and pathophysiological traits that are highly associated with addictive disorders in humans (FIG. 5) .
CNR1. Human CNR1 is located on chromosome 6 (6q14q15), with the coding region situated at the 5ʹend of exon 4. Several different CNR1 isoforms vary in expression across brain regions, although each of the main mRNA variants expresses the same exon 4 that encodes the CB1R protein 148 . Indeed, CNR1 exhibits substantial functional conservation, with few common missense variants in the CB1R protein being expressed 148 .
One of the first CNR1 variants explored in relation to drug abuse was the AATtriplet repeat ((AAT) n ) microsatellite polymorphism in the 3ʹuntranslated region, located close to the exon 4 translational start site 148 . Unfortunately, direct functional evidence is lack ing to understand its relevance to eCB processing, but the increased number of repeats is speculated to result in reduced CB1R expression 149 . Increased frequency of long (AAT) n was initially observed in an intravenous drugdependent nonHispanic US white population 150 , and this was partially supported in subsequent evalua tions of AfroCaribbean individuals 151 . Some reports Nature Reviews | Neuroscience 
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failed to replicate the original finding 148, 152 , but a meta analysis of multiple variants of CNR1 in white popula tions specifically identified the (AAT) n polymorphism (n > 16 repeats) as the only significant association with illicit SUDs 153 . Interestingly, the (AAT) n polymorphism has been linked with reduced amplitude of the frontal lobe P300 eventrelated brain potential, a disruption that has been suggested as a neurobiological endophenotype of impaired cortical processing in drug abusers 146 . Additional single nucleotide polymorphisms (SNPs) of CNR1 have been investigated, the most frequent of which is a silent intragenic biallelic polymorphism (G1359A; rs1049353). This exon 4 synonymous mutation does not change the amino acid sequence of the mature protein, but the SNP is speculated to affect mRNA stability or pro tein translation in a way that could alter CB1R function. Several investigations, although not all congruent, sug gest an association of the CNR1 G1359A polymorphism with substance abuse. For example, the Aallele is asso ciated with severe alcoholism, specifically in relation to enhanced withdrawal delirium in white patients 154 and enhanced impulsivity in Native Americans with a high lifetime prevalence of substance dependence 155 . The G1359A variant has also been associated with heroin abuse in a white population, but with the Aallele con ferring protection and the G/G genotype conferring addiction risk 156 . Additional studies are clearly needed to determine whether the riskversusprotection profile might depend on the drug class.
Aside from the G1359A SNP, most of the other CNR1 variants reported to be associated with addiction are not within the coding region; this is not surprising, considering that it is now evident that most variation in the genome falls outside proteincoding regions 157 . The rs2023239 variant, representing a T to C polymorphism in the intronic region upstream of exon 3, has been shown to relate to CB1R levels measured in postmortem brain tissue 158 and in vivo using PET imaging 94 , with the Callele being associated with enhanced CB1R levels in the normal human brain. As discussed above, increased CB1R in ani mal models is predictive of addiction vulnerability and, indeed, the rs2023239 SNP has been linked to a gen eral liability for substance abuse 148 . Individuals with the Callele use greater amounts of cannabis, exhibit higher cannabis dependency and experience greater negative affect and craving for cannabis following withdrawal 159 . The rs2023239 minor allele also associates with increased activation in rewardassociated brain areas (as measured by blood oxygenation leveldependent (BOLD) imaging) to cannabisrelated cues 160 . rs2023239 Callele carriers also have enhanced alcohol cueelicited brain activa tion in the PFC, NAc and midbrain (consistent with the VTA and surrounding regions), greater subjective reward when consuming alcohol, a strong correlation between cueelicited brain activation and alcohol consumption measures, and a strong association with alcoholuse disorder and craving measures 161 . Several CNR1 haplotype blocks have also been linked with addiction. When analysed as a haplotype (TAG), three SNPs (rs806379, rs1535255 and rs2023239) in the distal region of intron 2 of the CNR1 gene were sig nificantly associated with polysubstance abuse in adults from different ethnicities 148 . Moreover, Agrawal et al. 162 demonstrated an association between a CNR1 haplo type (rs806380, rs806368 and rs754387) and cannabis dependence (the majority of these individuals also met criteria for alcohol dependence). The rs806380 SNP proximal to the TAG haplotype has also been linked with the development of cannabisdependence symptoms (protective effect of Gallele). Other haplotypes have been reported to associate with either low (rs6454674, rs806380, rs806377 and rs1049353: GGCC) or increased (TACC and GACC) risk for cannabis dependence 163 . However, inconsistent and nominal significance has been reported in replication studies of cannabis dependence in adolescent and young adult populations 164 and for other haplotypes in substance abuse populations 165 . Overall, although the majority of genetic investigations suggest genes primarily studied to date in relation to genetic associations with addiction are CNR1 (part a) and fatty acid amide hydrolase (FAAH) (part b). Human CNR1, which encodes cannabinoid 1 receptor (CB1R), maps to chromosome 6, specifically in the cytogenetic band 6q14-q15, and is transcribed from the minus strand (3ʹ-to-5ʹ orientation) of the DNA. The gene contains four exons, with the protein-coding region being located at the 5ʹ-end of exon 4 (REFS [146] [147] [148] . There are multiple mRNA variants of CNR1, with the prominent form encoding the canonical 472-amino-acid-long protein. The FAAH gene is located on human chromosome 1, 1p35-p34, and is transcribed from the plus strand (5ʹ-to-3ʹ orientation). The gene contains 15 exons, with functional protein domains being encoded across multiple exons. Recently, another FAAH gene, FAAH2, was identified on chromosome X in cytogenetic band Xp11.21; the encoded protein is composed of 532 amino acids and shares about 20% sequence identity with the canonical protein FAAH1 (REF. 147 ). There is evidence, although not all consistent, that genetic variants (arrows) associated with addiction and related phenotypes, such as reward sensitivity, impulsivity and negative affect, are located within exon 4 (rs1049353), introns (rs2023239, rs1535255 and rs806380) and the 3ʹ-untranslated region (AAT-triplet repeat; rs806368) of CNR1 (REFS 159, (146) (147) (148) . For the FAAH gene, the polymorphic variant most associated with substance-use disorders is rs324420 (exon 3) 166, 146, 147 .
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an association between CNR1 variants and aspects of SUDs, the data are not definitive and no causative loci have been described to date. What seems most consist ent in the human genetic studies is a relevance to drug cue sensitivity and craving, which would complement the preclinical animal studies that demonstrate their direct link to the ECS.
FAAH.
Few genetic investigations have focused on other components of the ECS, with FAAH being the second gene mostoften studied in relation to addiction, based on AEA's important functional role. Human FAAH is located on chromosome 1p35p34 and has 15 exons, with functional protein domains being encoded across multiple exons. A SNP that has been highly investigated is rs324420, which is located in exon 3 and results in a missense mutation of a C-A replacement at position 385, leading to a proline to threonine change at protein position 129 (REF. 166 ). This C385A SNP is functional and is thought to result in reduced FAAH expression and enzyme activity, such that individuals with the A/A genotype have enhanced plasma concentrations of AEA and other Nacylethanolamine FAAH substrates 167 . Although some studies have not observed associa tions between the C385A polymorphism and SUDs, existing evidence implicates this genetic disruption in addictionrelated behaviours in different races and ethnicities 147 . Specifically, the A/A genotype associates with reduced vulnerability for cannabis dependence in white adults, whereas the C/C genotype associates with increased craving and negative affect during cannabis withdrawal. Initial studies failed to detect a link between the A/A genotype and alcohol or nicotine dependence 168 , although recently an overrepresentation of C/C carri ers was observed among individuals consuming levels of alcohol that put them at increased risk of alcoholrelated problems 169 . Carriers of the FAAH C385A SNP display increased ventral striatal reactivity associated with delay discounting, a behavioural index of impulsivity and reward sensitivity 170 and a markedly decreased relation ship between threatrelated amygdala reactivity and trait anxiety, similar to patterns observed in individuals with high familial risk for alcoholism 171 . These findings sug gest that dysregulation of FAAH function through the C385A polymorphism confers increased impulsivity and increased anxiety sensitivity.
Collectively, recent studies of CNR1 and FAAH genetic variants generally suggest an association with endophenotypes implicated in addiction susceptibility, including reward sensitivity, impulsivity and negative affect, consistent with preclinical evidence linking the ECS to such behaviours. Gene-gene interactions within the ECS may also be relevant to vulnerability, as there seem to be additive interactions between variants of the FAAH (C385A; rs324420) and CNR1 (rs2023239) genes, resulting in heightened neural responses in reward related brain areas to cannabis cues and moresevere negative affect during cannabis abstinence 159, 160 . Growing evidence of an eCB influence on epigenetic mechanisms suggests an additional but understudied way in which EC signalling may contribute to addiction
. Clearly, a major confounding factor of most investigations to date is the small population size used, emphasizing the need for replication studies and studies using larger popula tions. The few existing agnostic genomewide approaches have not identified eCBrelated genes in relation to SUDs interrogated thus far. However, the contribution of endo phenotypes along the continuum between genotype and drugabuse phenotype has not been interrogated, despite the complex nature of nonMendelian addictive disor ders. The lack of systematic consideration of behavioural traits limits the possibility to understand the full reper toire of the ECS to individual vulnerability to addiction. Moreover, the functional consequences of the variants (causal or correlated) are unknown, which makes coming to definitive conclusions challenging.
Summary and future directions
Although enhancement of eCB levels does not produce rewarding effects per se, eCB signalling at cannabinoid receptors participates in the mediation and modulation of both natural and druginduced reward. Brain eCB content is modulated by most drugs of abuse and natural rewards, and a robust CB1R influence on the motivation to con sume distinct classes of abused drugs and the association of CNR1 polymorphisms with aberrant reward process ing and addictive behaviours strongly implicate CB1Rs in the aetiology of addiction. Longterm drug use leads to neuroadaptive downregulation of eCB signalling resulting from diminished CB1R and/or CB2R function as well as possible disruptions in eCB biosynthesis and/or clearance. This blunting of eCB function may contribute to known susceptibility factors for relapse, namely, increased stress
Box 2 | Endocannabinoid influence on epigenetic mechanisms
Epigenetic influences are functionally relevant changes to the genome that do not involve disruptions in the nucleotide sequence of DNA. Examples of epigenetic mechanisms include DNA methylation, post-translational histone modification, nucleosome positioning and silencing associated with small non-coding RNAs (such as microRNAs and small interfering RNAs). Recent evidence demonstrates that epigenetic factors can regulate the expression of endocannabinoid (eCB)-related genes and that eCBs may themselves induce epigenetic alterations 194 . For example, DNA hypermethylation of CNR1 (the gene encoding cannabinoid 1 receptor (CB1R)) results in downregulation of transcription in the CNS and immune system, whereas decreased DNA methylation can result in increased fatty acid amide hydrolase (FAAH) transcription; these processes have been implicated in several pathologies, including colon cancer and late-onset Alzheimer disease. Conversely, eCB-induced alterations in enzymes influencing histone modification may disrupt the transcription of several genes, including those encoding various neurotransmitter systems. In rodents, early life stress (maternal separation) is associated with elevated DNA methylation of the CNR1 promoter 195 , which, through a resultant decrease in CB1R expression, could contribute to affective dysregulation and addiction susceptibility later in life. Several studies implicate increased epigenetic influences following chronic Δ 9 -tetrahydrocannabinol (Δ 9 -THC) exposure. Cannabis-dependent patients present robust methylation of the CNR1 promoter in association with diminished CNR1 mRNA in peripheral blood cells 196 . Furthermore, offspring of maternal cannabis users exhibit histone methylation and dysregulated mesolimbic dopamine D 2 receptor expression 197 , and adolescent Δ 9 -THC exposure is associated with nucleus accumbens (NAc) chromatin modifications and concurrent upregulation of the opioid neuropeptide proencephalin gene 198 . Prenatal alcohol exposure increases expression of the regulatory microRNA miR-26b (which targets the 3ʹ-untranslated region of the CNR1 transcript) and decreased CNR1 transcription in the adult mouse brain 199 . Thus, growing evidence suggests that there are eCB-related epigenetic influences following drug exposure. responsivity, increased negative affect, inefficient extinc tion of drugrelated memories and increased drugseeking behaviour and drug craving. Recent preclinical evidence demonstrates the efficacy of eCBclearance inhibitors for ameliorating these behavioural abnormalities, which might offer future therapeutic interventions for addic tion disorders. Importantly, because eCBs are generally produced in a synapsespecific manner, eCBclearance inhibitors may preferentially facilitate eCB signalling in specific circuits engaged by distinct stimuli (for example, stress or drugassociated cues) and therefore could pre sent fewer unwanted behavioural effects than are pro duced by exogenous agonists that produce widespread cannabinoid receptor activation.
Despite growing attention being given to the cannab inoids, there are still notable gaps in our understand ing of the eCB influence on reward and addiction. The ECS plays a prominent part in neuronal guidance and brain development 172 and, as such, disruptions in eCB function at an early age probably have substantial con sequences for adult brain function. This is underscored by increasing evidence of the longterm consequences of prenatal or adolescent cannabinoid exposure 173, 174 . Although the effects of early life exposure to non cannabinoid drugs are well studied, the specific con tributions of persistent druginduced disruptions in eCB signalling on adult neural function and behaviour are not understood. Robust bidirectional interactions between the ECS and sex hormones are now recog nized 175 , but few studies have characterized possible sex differences in the eCB influence on reward func tion, addiction and cognitive processing. There are also substantial limitations in the interpretation and replica tion of genetic analyses of the eCB influence in addic tion, owing to heterogeneity of the populations, drug classes, polysubstance use and even druguse pheno types examined. Largescale future studies across dif ferent populations and drug classes will be critical to understanding the relative effect and causal nature of ECSrelated genetic mutations in the vulnerability to addictive disorders. Filling these gaps of knowledge is critical, given the important need for scientific data to help guide current discussions and changes being made in marijuanalegalization policies.
